A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, King C. Chan et al.|Clinical Cancer Research|2022Cited by 22
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Unknown|2023Cited by 0
Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Unknown|2023Cited by 0
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Unknown|2023Cited by 0
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell CarcinomaJohn A. Ligon, John Glod, R. Taylor Sundby et al.|Unknown|2023Cited by 0